TP53 and neuroblastoma: Peirce and Findley demonstrated Nutlin-3’s ability to sensitize p53-null neuroblastoma cells to doxorubicin (162), but such first-generation MDM2 inhibitors were limited by poor bioavailability and pharmacokinetics, which hindered their in vivo efficacy (163).